home / stock / prax / prax news

PRAX News and Press, Praxis Precision Medicines Inc. From 11/17/20

Stock Information
Company Name: Praxis Precision Medicines Inc.
Stock Symbol: PRAX
Market: NASDAQ
Website: praxismedicines.com
Menu
PRAX PRAX Quote PRAX Short PRAX News PRAX Articles PRAX Message Board
Get PRAX Alerts

News, Short Squeeze, Breakout and More Instantly...
PRAX - Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder

- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 - CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of th...
PRAX - INO, ACB, REV and OGI among midday movers

Gainers: Greenland Technologies (GTEC) +170%.Revlon (REV) +86%.Summit Wireless Technologies (WISA) +50%.Trxade Group (MEDS) +29%.Inovio Pharmaceuticals (INO) +23%.Xperi Holding (XPER) +21%.Pulse Biosciences (PLSE) +21%.Aptevo Therapeutics (APVO) +21%.Boqii Holding (BQ) +20%.StarTek (SRT)...

PRAX - Trxade Group, OPKO Health leads healthcare gainers; Arena Pharmaceuticals, Voyager Therapeutics among major losers

Gainers: Trxade Group (MEDS) +35%, OPKO Health (OPK) +19%, Altimmune (ALT) +17%, Sientra (SIEN) +16%, Fulgent Genetics (FLGT) +8%.Losers: Arena Pharmaceuticals (ARNA) -25%, Voyager Therapeutics (VYGR) -21%, Aurora Cannabis (ACB) -21%, ...

PRAX - Praxis Precision Medicine plummets 27% on clinical hold on lead drug

Recent IPO Praxis Precision Medicines ([[PRAX]] -27.0%) craters on average volume in reaction to the FDA's clinical hold on its Investigational New Drug ((IND)) application for lead candidate PRAX-114, an extrasynaptic-preferring GABAa receptor positive allosteric modulator, for the potential...
PRAX - Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today anno...

PRAX - Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today anno...

Previous 10 Next 10